Immunocore Holdings Ltd

IMCR

NASDAQ. Currency in USD

59.98 -2.83 ( -4.51% )

Real time prices: December 01

Market Cap.
2.87B
Beta (5Y monthly)
-
Price/Earnings
6.07
EPS (TTM)
10.14
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
562,571
1y Target Est.
72.45
Day's Range
57.31
-
62.99
52 Week's Range
18.43
-
69.06

Historical Summary

Performance
EPS growth
Share Buybacks

About Immunocore Holdings Ltd

Sector
Healthcare
Industry
Biotechnology
Website
https://www.immunocore.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
43.90M
Employees
324
Address
92 Park Drive, Abingdon, United Kingdom, OX14 4RY
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest news

BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics
BioNTech (BNTX) Inks Research Deal With Ryvu Therapeutics

BioNTech (BNTX) signs a research collaboration agreement with Ryvu Therapeutics to develop small molecule programs...
By Zacks Investment Research - 18 hours ago

Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review
Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review

The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged...
By Zacks Investment Research - 19 hours ago

Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 30, 2022

Upgrades For Avadel Pharmaceuticals PLC (NASDAQ:AVDL), Jefferies upgraded the previous rating of Hold to Buy....
By Benzinga - 1 day ago

Where Immunocore Hldgs Stands With Analysts
Where Immunocore Hldgs Stands With Analysts

Over the past 3 months, 7 analysts have published their opinion on Immunocore Hldgs (NASDAQ:IMCR)...
By Benzinga - 1 day ago

7 Analysts Have This to Say About Immunocore Hldgs
7 Analysts Have This to Say About Immunocore Hldgs

Analysts have provided the following ratings for Immunocore Hldgs (NASDAQ:IMCR) within the last quarter: Bullish...
By Benzinga - 1 day ago

Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal
Axsome (AXSM) Gains as Alzheimer's Agitation Study Meets Goal

Axsome's (AXSM) phase III ACCORD study evaluating AXS-05 for treating Alzheimer's disease agitation met the...
By Zacks Investment Research - 2 days ago

Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study

Nabriva (NBRV) posts positive top-line data from the phase I study evaluating oral and intravenous...
By Zacks Investment Research - 2 days ago

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why
Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase...
By Zacks Investment Research - 3 days ago